The April 29 approval of Seattle-based Dendreon's prostate cancer vaccine, Provenge (sipuleucel ... controlled trial (Immunotherapy for Prostate Adenocarcinoma Treatment; IMPACT), the results ...
In addition, as sipuleucel-T can affect survival, this should be considered in the design of future clinical trials, and might be an appropriate stratification factor in studies with a survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback